Sort   by:  
 Page size 
ProteomicsProtein and Signaling Pathway Responses to rhIL-6 Intervention before Lobaplatin Treatment in Osteosarcoma Cells using LC-MS/MS
Lobaplatin is a third-generation platinum-based antineoplastic agent and is widely used for osteosarcoma treatment before and after tumor removal. However, treatment failure often results from lobaplatin drug resistance. In our study, we found that SaOS-2 and SOSP-9607 osteosarcoma cells became less...
ORGANISM(S): Homo sapiens (Human) 
2021-02-25 | PXD021564 | Pride
Human Lobaplatin Rhil-6 Osteosarcoma Liquid chromatography-tandem mass spectrometry 
ProteomicsProtein and Signaling Pathway Responses to rhIL-6 Intervention before Lobaplatin Treatment in Osteosarcoma Cells using Quantitative Phosphoproteome Analysis
IL-6 plays a pivotal role in the process of drug resistance to kinds of chemotherapeutics including lobaplatin. However, the underlying changes of phosphoproteins and related signaling pathways in the posttranslational modification level is still uncover. In our study, a quantitative phosphoproteome...
ORGANISM(S): Homo sapiens (Human) 
2022-02-17 | PXD025970 | Pride
Human Phosphoproteome analysis Lobaplatin Il-6 Osteosarcoma 
GenomicsFar upstream element-binding protein 1 confers lobaplatin resistance via facilitating the arachidonic acid signaling in osteosarcoma
Far upstream element-binding protein 1 confers lobaplatin resistance via facilitating the arachidonic acid signaling in osteosarcoma
PRJNA867349 | ENA
TranscriptomicsFar upstream element-binding protein 1 confers lobaplatin resistance via facilitating the arachidonic acid signaling in osteosarcoma
Purpose: To understand the mechanism of lobaplatin resistance and explore effective strategies for patients with osteosarcoma. Results: The expression of FUBP1 was remarkably elevated in osteosarcoma cell lines and clinical specimens compared with osteoblast cells and the normal bone. High expressio...
ORGANISM(S): Homo sapiens 
2023-05-17 | GSE210740 | GEO
UnknownCleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells.
Not available
S-EPMC6389936 | biostudies-literature
UnknownEfficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study.
Not available
S-EPMC10186371 | biostudies-literature
UnknownEnhancing lobaplatin sensitivity in lung adenocarcinoma through inhibiting LDHA-targeted metabolic pathways.
Not available
S-EPMC11649076 | biostudies-literature
UnknownProtein and Signaling Pathway Responses to rhIL-6 Intervention Before Lobaplatin Treatment in Osteosarcoma Cells.
Not available
S-EPMC8006349 | biostudies-literature
UnknownHematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab.
Not available
S-EPMC8566976 | biostudies-literature
UnknownComparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo.
Not available
S-EPMC7384850 | biostudies-literature
Sort   by:  
 Page size